Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Innate Lymphoid Cell Engagers (ILCEs): Targeting Innate Lymphoid Cells through a Bispecific Engager for the Resolution of Chronic Inflammation

Project description

A new immune approach to chronic inflammation

Many chronic inflammatory diseases, such as rheumatoid arthritis and spondyloarthropathies, are currently managed with medications that suppress the immune system. The mainstay of treatment is immunosuppressive therapy. But this comes with downsides, including increased susceptibility to infections and limited long-term relief. With this in mind, the ERC-funded ILCE project explores a new curative treatment approach involving innate lymphoid cells (ILCs), a type of immune cell involved in inflammation. Specifically, it will develop an ILC engager that can precisely target and reprogramme the immune response to resolve inflammation naturally.

Objective

Chronic inflammatory diseases, such as rheumatoid arthritis (RA) and spondyloarthropathies (SpA) represent a persistent healthcare challenge, requiring life-long management because of treatments with limited long-term efficacy. The key to a breakthrough may lie in the strategic engagement of Innate Lymphoid Cells (ILCs), whose potential in resolving inflammation and reprogramming tissue memory emerges from the recent ERC-funded research by Rauber et al. (2024). The study published in Nature Immunology elucidates the physiological function of ILCs to control inflammation. Building on this, we propose an innovative ILC engager (ILCE), aiming to harness natural pathways of resolution of inflammation and to offer a significant improvement over anti-cytokine therapies. Our approach bypasses generalized immunosuppression and thereby reduces the risk of infection by maintaining the body's acute inflammatory response. The development of an ILCE holds the promise to gain a new class of precise and efficacious therapeutics for chronic inflammatory diseases, revolutionizing patient outcomes by tailoring treatments to the nuanced pathophysiology of inflammation.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITATSKLINIKUM ERLANGEN
Net EU contribution
€ 150 000,00
Address
MAXIMILIANSPLATZ 2
91054 Erlangen
Germany
Region
Bayern Mittelfranken Erlangen, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)